CaBP8 Inhibitors
CaBP8 inhibitors comprise a specialized group of chemical compounds designed to selectively impede the activity of the Calcium-Binding Protein 8 (CaBP8). These inhibitors are characterized by their ability to interact with the protein in a manner that disrupts its calcium-binding capabilities, which is a critical aspect of its normal function within cellular signaling pathways. The inhibition of CaBP8 is a result of these compounds binding to the same sites or altering the conformation of the protein in such a way that its ability to bind calcium ions is compromised. The precise mechanisms of action can vary among different inhibitors within this class but are unified by the outcome of reduced CaBP8 activity. The calcium ion binding is fundamental to the protein's role in signaling, as it often leads to conformational changes that enable interactions with other proteins and molecules within the cell, thus affecting a range of cellular processes.
The specificity of CaBP8 inhibitors is crucial; they are designed to target the unique structural features of CaBP8 without affecting other calcium-binding proteins. This is accomplished through the development of inhibitors that mimic the ionic properties of calcium or by creating molecules that bind to unique amino acid sequences within the CaBP8 structure. Through these interactions, the inhibitors can effectively prevent the protein from participating in calcium-mediated signaling pathways, ultimately leading to a decrease in the functional activity of CaBP8. The development of these inhibitors is rooted in an extensive understanding of the protein's structure and the critical regions involved in calcium ion coordination. By focusing on these key areas, CaBP8 inhibitors are able to exert their effects with high precision, ensuring that the downstream signaling events that rely on CaBP8 are attenuated, which could be pivotal for regulating processes where CaBP8 is a significant contributor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is a calcium channel blocker that can impede calcium influx into cells. Given that CaBP8 binds calcium, verapamil's action could reduce the availability of calcium for binding to CaBP8, thereby hindering its function. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene interferes with the release of calcium from the sarcoplasmic reticulum by acting on ryanodine receptors. By reducing cytosolic calcium concentrations, dantrolene could indirectly limit the activity of CaBP8, which relies on intracellular calcium to function. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is another calcium channel blocker that can decrease intracellular calcium levels. Its effect on cellular calcium homeostasis could result in reduced activation of CaBP8, which is dependent on calcium binding for its activity. | ||||||
Phenylarsine oxide | 637-03-6 | sc-3521 | 250 mg | $41.00 | 4 | |
Phenylarsine oxide is a compound that binds to vicinal dithiols and can affect protein-protein interactions. If CaBP8 interacts with other proteins through dithiol regions, this agent could disrupt those interactions, leading to inhibition of CaBP8 activity. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Bepridil is a calcium channel antagonist that reduces calcium entry into cells. By lowering intracellular calcium levels, bepridil could impede the calcium-binding ability of CaBP8 and thus its functional activity. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
2-APB affects calcium signal transduction by modulating inositol 1,4,5-triphosphate (IP3) receptors and store-operated channels. Altering calcium signaling and stores with 2-APB could therefore decrease the activity of CaBP8 by affecting its calcium-dependent regulatory mechanisms. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, leading to depletion of intracellular calcium stores. This disruption of calcium homeostasis could prevent CaBP8 from binding calcium and performing its regulatory functions. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Ryanodine locks ryanodine receptors in an open or closed state, disrupting normal calcium signaling. This disruption can lead to a decrease in the intracellular calcium level which is necessary for CaBP8 activity. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Amlodipine is a long-acting calcium channel blocker that reduces intracellular calcium levels, which could interfere with calcium-dependent proteins like CaBP8. Its role in lowering calcium availability could thus indirectly inhibit the activity of CaBP8. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
SKF-96365 is an inhibitor of receptor-mediated calcium entry and store-operated channels. By inhibiting these channels, SKF-96365 can decrease intracellular calcium levels, potentially reducing CaBP8 activity by limiting the calcium available for binding to this protein. | ||||||